At ISPOR Europe 2022 in Vienna, the INTREPID Trial study, to which the PHARMO Institute participated, will be presented as poster presentation on Wednesday November 9th during the poster session (9:00-12:30 CET). Look for EPH198 poster entitled: Assessing the Validity of Netherlands Linked Routine Healthcare Resource Utilisation Data in the Investigation of Single-Inhaler Triple Therapy Effectiveness (INTREPID Trial).

In this study it was shown that linked HCRU data from the PHARMO Data Network were available for INTREPID patients with greater granularity than data generally available from prospectively collected patient recall of HCRU in pragmatic studies. Future studies should consider using linked routine hospital data alongside prospectively collected data in pragmatic trials in routine practice in the Netherlands.

Don’t miss the poster at ISPOR for a visual presentation on this study or have a look at the abstract by clicking read more

Share this article